Suppr超能文献

肌萎缩侧索硬化症患者无创通气后生存的预测因素。

Factors predicting survival following noninvasive ventilation in amyotrophic lateral sclerosis.

作者信息

Peysson S, Vandenberghe N, Philit F, Vial C, Petitjean T, Bouhour F, Bayle J Y, Broussolle E

机构信息

Faculté de Médecine Lyon Sud, Université Lyon 1, et Centre SLA, Hôpital Neurologique et Neurochirurgical, Hospices Civils de Lyon, Lyon, France.

出版信息

Eur Neurol. 2008;59(3-4):164-71. doi: 10.1159/000114037. Epub 2008 Jan 29.

Abstract

BACKGROUND/AIMS: The involvement of respiratory muscles is a major predicting factor for survival in amyotrophic lateral sclerosis (ALS). Recent studies show that noninvasive ventilation (NIV) can relieve symptoms of alveolar hypoventilation. However, factors predicting survival in ALS patients when treated with NIV need to be clarified.

METHODS

We conducted a retrospective study of 33 consecutive ALS patients receiving NIV. Ten patients had bulbar onset. We determined the median survivals from onset, diagnosis and initiation of NIV and factors predicting survival. Statistical analysis was performed using the Kaplan-Meier test and Cox proportional hazard models.

RESULTS

The median initial and maximal total uses of NIV were 10 and 14 h/24h. The overall median survival from ALS onset was 34.2 months and worsened with increasing age and bulbar onset of the disease. The median survival from initiation of NIV was 8.4 months and was significantly poorer in patients with advanced age or with airway mucus accumulation. Survival from initiation of NIV was not influenced by respiratory parameters or bulbar symptoms.

CONCLUSION

Advanced age at diagnosis and airway mucus accumulation represent poorer prognostic factors of ALS patients treated with NIV. NIV is a helpful treatment of sleep-disordered breathing, including patients with bulbar involvement.

摘要

背景/目的:呼吸肌受累是肌萎缩侧索硬化症(ALS)患者生存的主要预测因素。近期研究表明,无创通气(NIV)可缓解肺泡通气不足的症状。然而,接受NIV治疗的ALS患者生存的预测因素仍需明确。

方法

我们对33例连续接受NIV治疗的ALS患者进行了一项回顾性研究。其中10例患者为延髓起病。我们确定了从发病、诊断和开始使用NIV后的中位生存期以及生存的预测因素。使用Kaplan-Meier检验和Cox比例风险模型进行统计分析。

结果

NIV的初始和最大总使用时间中位数分别为10和14小时/24小时。ALS发病后的总体中位生存期为34.2个月,且随着年龄增长和疾病延髓起病而缩短。开始使用NIV后的中位生存期为8.4个月,高龄或气道有黏液积聚的患者生存期明显较差。开始使用NIV后的生存情况不受呼吸参数或延髓症状的影响。

结论

诊断时高龄和气道黏液积聚是接受NIV治疗的ALS患者预后较差的因素。NIV是治疗睡眠呼吸障碍的有效方法,包括延髓受累的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验